Clozapine and agranulocytosis: the REMS program explained

Clozapine is the most effective antipsychotic available — and it has been off-limits to most patients for decades because it carries a small but real risk of agranulocytosis, a dangerous drop in the white blood cells that fight infection. The Clozapine REMS (Risk Evaluation and Mitigation Strategy) is the FDA program built around that risk. It saves lives, and it has also limited access. In late 2024 and 2025, the FDA announced major changes to the program. This article explains how it works, why it exists, and what is changing.

What agranulocytosis is

Agranulocytosis means a near-total loss of granulocytes — the white cells that include neutrophils. Severe neutropenia, defined as an absolute neutrophil count (ANC) below 500/µL, leaves a person vulnerable to bacterial infections that can become life-threatening. Clozapine-associated severe neutropenia occurs in roughly 0.4–0.8% of patients exposed, and life-threatening agranulocytosis in roughly 0.05–0.1%. Most cases occur in the first six months of treatment, with the highest risk in the first 18 weeks. Risk after one year of continuous treatment becomes very low but never zero.

Why clozapine is worth the trouble

Multiple landmark trials, including the original 1988 Kane study and the more recent CATIE and CUtLASS trials, established clozapine as substantially more effective than any other antipsychotic for treatment-resistant schizophrenia. It is also the only antipsychotic with FDA approval to reduce suicide risk in schizophrenia and schizoaffective disorder. Long-term observational studies (notably the Finnish national register studies by Tiihonen and colleagues) have repeatedly found clozapine associated with lower all-cause mortality than other antipsychotics, despite the agranulocytosis risk. The benefit is real and large.

What the Clozapine REMS does

The REMS, summarised on the FDA REMS page, has historically included:

• Required certification of prescribers, pharmacies, and patients
• Required ANC blood draws on a defined schedule
• Reporting of ANC values into a central database before any dispensing
• A "stop" decision if the ANC fell below defined thresholds

The standard monitoring schedule

• Weekly for the first 6 months
• Every 2 weeks for months 6–12
• Every 4 weeks thereafter, indefinitely

The general population ANC threshold for continuing clozapine is ≥1500/µL. Treatment is interrupted at ANC <1000/µL and discontinued at ANC <500/µL. A separate, lower threshold applies to patients with Benign Ethnic Neutropenia (BEN), a condition more common in people of African and Middle Eastern descent in which a baseline neutrophil count below the standard threshold is normal and not associated with infection risk. Recognition of BEN was an important reform that allowed many patients to remain on clozapine who would previously have been forced off.

What is changing

In 2024 and 2025 the FDA announced reductions in some REMS requirements — notably moving away from mandatory ANC reporting before dispensing in many situations, while still requiring monitoring. The intent is to reduce the access barriers that have caused under-prescribing of clozapine in the US. Estimates suggest only a small fraction of US patients with treatment-resistant schizophrenia receive clozapine, far fewer than in countries with simpler monitoring systems. Patients and prescribers should check the most current FDA REMS guidance, because the rules are in transition.

Other haematological effects

Clozapine can also cause:

• Eosinophilia — usually transient, sometimes a marker of myocarditis
• Thrombocytopenia — rare
• Anemia — rare

The CBC drawn for ANC monitoring also captures these.

Other clozapine-specific safety issues

Clozapine carries five FDA boxed warnings: severe neutropenia, orthostatic hypotension/bradycardia/syncope, seizures, myocarditis/cardiomyopathy, and increased mortality in elderly patients with dementia-related psychosis. Each requires its own monitoring approach beyond the ANC. Constipation severe enough to cause bowel obstruction is a major and often-fatal complication that does not appear in the boxed warnings but is a leading cause of clozapine-related deaths in some cohorts; aggressive bowel regimens are now considered standard.

What patients should know

• The blood draws are non-negotiable, but they save lives.
• Most agranulocytosis happens in the first six months. Surviving the first 18 weeks dramatically reduces ongoing risk.
• Any new fever, sore throat, mouth ulcer, or signs of infection on clozapine warrants immediate ANC testing.
• Smoking and certain antibiotics meaningfully change clozapine levels — see our tobacco deep dive.
• Clozapine is one of the few medications where staying on it is statistically associated with longer life, despite the side effect burden.

The bottom line

Agranulocytosis is the side effect that has shaped the entire clinical culture around clozapine. It is rare, serious, and detectable. The REMS program is imperfect — it almost certainly keeps many patients off a medication that would help them — but it is also the reason clozapine remains on the market at all. The current direction of FDA policy is to keep the safety monitoring while loosening the bureaucratic friction. For patients with treatment-resistant symptoms, clozapine remains, by a wide margin, the most effective option.

For more, see our clozapine overview, CBC monitoring on clozapine, and clozapine vs other antipsychotics.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.